FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311667078> ?p ?o ?g. }

• W4311667078 endingPage "944" @default.
• W4311667078 startingPage "937" @default.
• W4311667078 abstract "Abstract Introduction Smokers with concurrent depression are less likely to achieve abstinence, even with pharmacotherapy. The purpose of this secondary data analysis was to evaluate if the presence of any depressive symptoms at baseline alters the effectiveness of bupropion and varenicline for smoking cessation. Aims and Methods Eligible participants were enrolled via the internet and randomized 1:1 to receive a 12-week supply of either bupropion (n = 465) or varenicline (n = 499). Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-2). Follow-up surveys were conducted at weeks 4, 8, 12, 26, and 52 to assess self-reported quit. The primary outcome was 7-day point prevalence abstinence at 12 weeks follow-up (end-of-treatment). Results Participants who endorsed any depressive symptoms (PHQ-2 &gt; 0; n = 280) were less likely to be quit at end-of-treatment compared to participants who did not endorse any symptoms (PHQ-2 = 0; n = 684) (OR = 0.56, 95% CI: 0.38 to 0.8, p = .003). Within the varenicline group, quit outcomes did not differ between those with and without depressive symptoms (21.3% vs. 26.9%, respectively). Within the bupropion group, however, those with symptoms had a significantly reduced quit rate compared to those without symptoms (7.0% vs. 17.3%, respectively). Conclusions The presence of even one symptom of depression at the start of a quit attempt may adversely affect quit outcomes. Patients should be assessed for depressive symptoms when planning to quit smoking as it may inform the approach to treatment. However, future studies are needed to confirm these findings. Implications Findings from the current study illustrate the importance of evaluating baseline sub-clinical depressive symptoms before a quit attempt using first-line pharmacotherapies. This secondary analysis of a large-scale randomized trial suggests that bupropion may be less effective for those with baseline depressive symptoms while varenicline may be equally effective for those with and without depressive symptoms" @default.
• W4311667078 created "2022-12-27" @default.
• W4311667078 creator A5012010351 @default.
• W4311667078 creator A5020868945 @default.
• W4311667078 creator A5052646822 @default.
• W4311667078 creator A5053586451 @default.
• W4311667078 creator A5056344854 @default.
• W4311667078 creator A5062487017 @default.
• W4311667078 creator A5067734183 @default.
• W4311667078 date "2022-12-15" @default.
• W4311667078 modified "2023-09-27" @default.
• W4311667078 title "Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms" @default.
• W4311667078 cites W1702723615 @default.
• W4311667078 cites W1979261550 @default.
• W4311667078 cites W1982134209 @default.
• W4311667078 cites W1982928267 @default.
• W4311667078 cites W1988272137 @default.
• W4311667078 cites W1993729509 @default.
• W4311667078 cites W1997437727 @default.
• W4311667078 cites W2007160641 @default.
• W4311667078 cites W2026718617 @default.
• W4311667078 cites W2028087632 @default.
• W4311667078 cites W2029521752 @default.
• W4311667078 cites W2055250100 @default.
• W4311667078 cites W2056007836 @default.
• W4311667078 cites W2069480407 @default.
• W4311667078 cites W2070192651 @default.
• W4311667078 cites W2075485200 @default.
• W4311667078 cites W2081438909 @default.
• W4311667078 cites W2107200746 @default.
• W4311667078 cites W2118061336 @default.
• W4311667078 cites W2124679681 @default.
• W4311667078 cites W2124905812 @default.
• W4311667078 cites W2127890858 @default.
• W4311667078 cites W2132322340 @default.
• W4311667078 cites W2142186991 @default.
• W4311667078 cites W2164386461 @default.
• W4311667078 cites W2173839198 @default.
• W4311667078 cites W2228339316 @default.
• W4311667078 cites W2316732422 @default.
• W4311667078 cites W2317321545 @default.
• W4311667078 cites W2340896985 @default.
• W4311667078 cites W2407654663 @default.
• W4311667078 cites W2418900875 @default.
• W4311667078 cites W2521818024 @default.
• W4311667078 cites W2563836337 @default.
• W4311667078 cites W2606412706 @default.
• W4311667078 cites W2612997660 @default.
• W4311667078 cites W2780234529 @default.
• W4311667078 cites W2793833453 @default.
• W4311667078 cites W2801645936 @default.
• W4311667078 cites W2810772340 @default.
• W4311667078 cites W2885484752 @default.
• W4311667078 cites W2916429144 @default.
• W4311667078 cites W3184366311 @default.
• W4311667078 cites W4210829139 @default.
• W4311667078 cites W4220829235 @default.
• W4311667078 doi "https://doi.org/10.1093/ntr/ntac288" @default.
• W4311667078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36520964" @default.
• W4311667078 hasPublicationYear "2022" @default.
• W4311667078 type Work @default.
• W4311667078 citedByCount "1" @default.
• W4311667078 countsByYear W43116670782023 @default.
• W4311667078 crossrefType "journal-article" @default.
• W4311667078 hasAuthorship W4311667078A5012010351 @default.
• W4311667078 hasAuthorship W4311667078A5020868945 @default.
• W4311667078 hasAuthorship W4311667078A5052646822 @default.
• W4311667078 hasAuthorship W4311667078A5053586451 @default.
• W4311667078 hasAuthorship W4311667078A5056344854 @default.
• W4311667078 hasAuthorship W4311667078A5062487017 @default.
• W4311667078 hasAuthorship W4311667078A5067734183 @default.
• W4311667078 hasConcept C118552586 @default.
• W4311667078 hasConcept C126322002 @default.
• W4311667078 hasConcept C139719470 @default.
• W4311667078 hasConcept C142724271 @default.
• W4311667078 hasConcept C162324750 @default.
• W4311667078 hasConcept C168563851 @default.
• W4311667078 hasConcept C2776867660 @default.
• W4311667078 hasConcept C2777053506 @default.
• W4311667078 hasConcept C2777843972 @default.
• W4311667078 hasConcept C2778529449 @default.
• W4311667078 hasConcept C2779908668 @default.
• W4311667078 hasConcept C2780687700 @default.
• W4311667078 hasConcept C3019858935 @default.
• W4311667078 hasConcept C500440147 @default.
• W4311667078 hasConcept C558461103 @default.
• W4311667078 hasConcept C71924100 @default.
• W4311667078 hasConceptScore W4311667078C118552586 @default.
• W4311667078 hasConceptScore W4311667078C126322002 @default.
• W4311667078 hasConceptScore W4311667078C139719470 @default.
• W4311667078 hasConceptScore W4311667078C142724271 @default.
• W4311667078 hasConceptScore W4311667078C162324750 @default.
• W4311667078 hasConceptScore W4311667078C168563851 @default.
• W4311667078 hasConceptScore W4311667078C2776867660 @default.
• W4311667078 hasConceptScore W4311667078C2777053506 @default.
• W4311667078 hasConceptScore W4311667078C2777843972 @default.
• W4311667078 hasConceptScore W4311667078C2778529449 @default.
• W4311667078 hasConceptScore W4311667078C2779908668 @default.

• next